

Resource Summary Report

Generated by ASWG on Aug 9, 2026

CD45

RRID:AB_2744403

Type: Antibody

Proper Citation

BD Biosciences Cat# 564047, RRID:AB_2744403

Antibody Information

URL: http://antibodyregistry.org/AB_2744403

Proper Citation: BD Biosciences Cat# 564047, RRID:AB_2744403

Target Antigen: CD45

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD45

Description: This monoclonal targets CD45

Target Organism: human

Clone ID: HI30

Antibody ID: AB_2744403

Vendor: BD Biosciences

Catalog Number: 564047

Alternative Catalog Numbers: 564048

Record Creation Time: 20250819T212638+0000

Record Last Update: 20250819T225828+0000

Ratings and Alerts

No rating or validation information has been found for CD45.

No alerts have been found for CD45.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Saini M, et al. (2025) StealTHY: An immunogen-free CRISPR platform to expose concealed metastasis regulators in immunocompetent models. *Cell*, 188(26), 7591.

Van Laethem JL, et al. (2025) CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. *Cell reports. Medicine*, 6(10), 102407.

Champiat S, et al. (2025) Nanrilkefusp alfa (SOT101), an IL-15 receptor ?? superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers. *Cell reports. Medicine*, 6(2), 101967.

Das Adhikari U, et al. (2025) Immunometabolic defects of CD8+ T cells disrupt gut barrier integrity in people with HIV. *Cell*.

Pastor Y, et al. (2024) A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease. *Cell reports. Medicine*, 5(3), 101467.

Lin F, et al. (2024) Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. *Cell*, 187(26), 7470.

Nava Lauson CB, et al. (2023) Linoleic acid potentiates CD8+ T cell metabolic fitness and antitumor immunity. *Cell metabolism*, 35(4), 633.

Hunter AM, et al. (2021) Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 27(22), 6095.

Dziedzic K, et al. (2021) Release of adenosine-induced immunosuppression: Comprehensive characterization of dual A2A/A2B receptor antagonist. *International immunopharmacology*, 96, 107645.

Chow MT, et al. (2019) Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. *Immunity*, 50(6), 1498.